46
February / March 2012
Meeting Preview-Separation Science in
an Evolving Pharmaceutical Industry The Chromatographic Society Spring Symposium & Annual General Meeting
Banqueting Suite, Stadium of Light, Sunderland - May 30th-31st, 2012
2012 promises to be yet another busy year for The Chromatographic Society in terms of its scientific meetings. Indeed, by the time you read this meeting preview, our first meeting of the year, dealing with the highly topical area of ’Chromatographic Characterisation and Purification Techniques for BioPharm‘ may already have taken place at GSK, Stevenage on the 14th and 15th of March. Later on in the year the Society will be one of the principal partners involved in the ISC 2012 international symposium taking place on September 9th -14th at Torun, Poland in September and will be an active sponsor of PBA 2012 taking place in Mumbai, India on September 24th – 27th. The end of the year will see a proposed meeting, back in the UK (venue and full title to be announced) on the impact and role of separation science in clinical chemistry.
However, as always, the main event of the year is the Society’s Spring Symposium and Annual General Meeting which will take place this year at the Banqueting Suite of the Stadium of Light, the home of Sunderland AFC, the English Premier League football club. This will be the Society’s fifth visit in total to Sunderland and the fourth to this particular venue, demonstrating the Society’s national reach with regular meetings in the North West region also complementing the main diet of meetings in London and the South East. In 2008 a highly successful and memorable Spring Symposium took place at another football venue, the Madjeski Stadium, Reading but since then the Society has reverted to type, holding its Spring Symposium on major pharmaceutical company R&D sites and covering topics relevant to these locations. Despite the meeting theme this time round ’Separation Science in an Evolving Pharmaceutical Industry‘, the wider roots of The Chromatographic Society will be acknowledged. In particular, the opening sessions on Wednesday 30th will mark a return to the pattern that existed up to the mid-1990s with the Spring Symposium consisting primarily of state-of-the-art overviews covering core areas of separation science. Talks of this nature will be given on topics such as solid phase extraction, chiral separations and LC column technology. Also, by way of a nod of acknowledgement towards the host location, the speakers in this session will be drawn from graduates of the University of Sunderland’s
B.Sc. Chemical and Pharmaceutical Science course who have gone on to take up high profile roles in the UK
Speakers for May 30th – 31st will include (from left to right) Lee Williams, Melissa Hanna-Brown and Tim Liddicoat
pharmaceutical industry. By the time of the meeting, this programme will have served the pharmaceutical industry well for exactly a quarter of a century and, in line with current trends, is being replaced by a B,Sc. BioPharmaceutical Science programme. The Wednesday evening social event will also have a university connection, taking place in the University of Sunderland’s newly refurbished Sciences Complex. The event will involve a tour of the complex (featuring a £1 million investment in new analytical instrumentation), a talk on chromatographic instrumentation over the years and a hot buffet with drinks. For those with an unfortunate predisposition to the latter, it should be noted that the complex is a mere stone’s throw from the city’s thriving bar and nightclub area. If previous history is to be repeated, the delights of this area might prove to be opportune! The sessions on Thursday 31st May have a more pharmaceutical focus but have a wider scope in the sense that the entire spectrum of the pharmaceutical industry will be covered. This is highly appropriate in that the North East of England is now one of the most important pharmaceutical hubs in the UK (
http://www.nepharma.co.uk/) and has a strong pharmaceutical manufacturing presence (MSD, GSK, Sanofi Aventis, Piramal Healthcare, Shasun Pharmaceuticals and Aesica Pharmaceuticals). Rather than having sessions on the individual stages of the R&D
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60
